Moffett Field, California, 10/03/2006

Changene Lab, a NASA industry partner that develops Pincta-Cal, an osteogenic agent for space missions, has signed a sales agreement with Pharma Power Biotec, a well-established pharmaceutical company in Taiwan. The value of the deal is estimated to be worth US$500,000 – $1,000,000.

"Taiwan is an important market in Asia," Frank Chang, CEO of Changene Lab said. "At the point when we landed in Taiwan, we have established a foundation to expand our product line throughout the entire Pacific Rim, major markets include Japan, China, South Korea, and Australia. This strategic achievement is more than the monetary value of the deal itself."

Mr. Chang also recognized the Commercial Service’s contribution to facilitating the deal, commenting, "We sincerely appreciate the Commercial Service's help and guidance. It has significantly reduced the time taken for us to gain recognition and orders in off-shore markets."

Commenting on Taiwan’s strategic positioning, J. M. Chang, President of Pharma Power Biotec, observed, "Taiwan has marked her significance in the high tech industry and is ready to make another one. The biotech and biopharmaceutical industries are emerging as the next trend in Taiwan. We are willing to take the lead."

"Changene Lab is an outstanding Silicon Valley example of what small businesses can achieve in the global marketplace," commented Gabriela Zelaya, Trade Specialist of the U.S. Commercial Service Export Assistance Center (USEAC) in San Jose. "The Commercial Service plays a vital role in helping these firms increase their exports, which supports jobs in the United States."

To find out more about the Featured U.S. Exporters (FUSE) and other marketing programs or research we provide, please click here.